Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Takara Bio Inc. ( (JP:4974) ) has shared an update.
Takara Bio Inc. has revised its financial forecasts for the fiscal year ending March 31, 2026, due to a sluggish global life sciences market and challenges in acquiring new projects in Japan. The company anticipates a significant decline in net sales, operating profit, and net income, leading to a decision not to issue a year-end dividend. Additionally, a portion of executive remuneration will be waived to address the financial shortfall.
The most recent analyst rating on (JP:4974) stock is a Hold with a Yen931.00 price target. To see the full list of analyst forecasts on Takara Bio Inc. stock, see the JP:4974 Stock Forecast page.
More about Takara Bio Inc.
Takara Bio Inc. operates in the life sciences industry, focusing on bioindustry and gene therapy businesses. The company is involved in research and development activities and provides services related to contract development and manufacturing organization (CDMO).
Average Trading Volume: 403,638
Technical Sentiment Signal: Strong Sell
Current Market Cap: Yen109.9B
Learn more about 4974 stock on TipRanks’ Stock Analysis page.